Acute onset of fingolimod-associated macular edema

PURPOSE: Fingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs within the first 4 months of therapy. Macular ede...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Am J Ophthalmol Case Rep
Egile Nagusiak: Soliman, Mohamed Kamel, Sarwar, Salman, Sadiq, Mohammad A., Jack, Loren, Jouvenat, Neil, Zabad, Rana K., Kedar, Sachin, Nguyen, Quan Dong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2016
Gaiak:
Case report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5757484/
https://ncbi.nlm.nih.gov/pubmed/29503930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajoc.2016.09.005
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak